Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions

Christine Clavel, Marie Masure, Isabelle Putaud, Kathleen Thomas, Jean-Paul Bory, René Gabriel, Christian Quereux, Philippe Birembaut

Abstract

Aim—To test a new assay for the detection of human papillomavirus (HPV) DNA, hybrid capture II (HC II), compared with the previous commercialised hybrid capture I (HC I) and polymerase chain reaction (PCR) results on cervical scrapes from fresh cone excision biopsy samples.

Methods—The three methods were used on cervical scrapes from 42 fresh cone excision biopsy samples. There were nine metaplastic and inflammatory lesions, five low grade lesions, and 28 high grade lesions. PCR was performed using the general primers GP5+/GP6+. The viral load of high risk HPV DNA was estimated by the ratio of relative light units to positive control values in the samples.

Results—The sensitivity of HC I for the detection of high grade lesions was 71.4%, while it was 92.8% for HC II and 96.4% for the PCR. Considering only the absence of detectable cervical in situ neoplasia, the specificity was 88.9% for HC I, 66.7% for HC II, and 66.7% for PCR. With HC II, for a ratio of cervical sample to normal control of > 200, the sensitivity for the detection of high grade lesion was only 34.6% with a specificity of 66.7%.

Conclusions—HPV detection with the HC II assay is more sensitive than the previous HC I and represents a more convenient and easier test than PCR for routine use. Nevertheless the viral load estimated with this test cannot be a reliable predictive indicator of high grade lesions.

(J Clin Pathol 1998;51:737–740)

Keywords: hybrid capture; human papillomavirus; cervical intraepithelial neoplasia

DNA of the high risk human papillomavirus (HPV) types (including types 16, 18, 31, 33, 35, and 39) is found in over 90% of cervical cancers and in their precursor lesions, while the low risk HPV types (including types 6 and 11) are associated almost exclusively with benign lesions.1–4 Infections with high risk HPV are associated with a relative risk of between 8 and 11 for the development of squamous intraepithelial lesions (SIL)5 and only low grade SIL containing high risk HPV types progress to high grade disease.6 This is the reason for the increasing interest in using HPV DNA detection, either alone or in addition to classical cytological examination, as a method for screening cervical carcinoma or for triaging women with a cytological diagnosis of atypical squamous cells of undetermined significance (ASCUS) in their cervical smears.7–9 HPV DNA testing in exfoliated cervical cells offers a potentially automatic and cheap diagnostic assay without the sampling problems and subjectivity of cervical cytology. However, such an approach needs a specific, sensitive, reliable, and easy to perform method. The polymerase chain reaction (PCR) is the best and most sensitive test to date. Moreover, its routine application is very much improved by using a non-radioactive enzyme immunoassay detection procedure.10–12 These methods are not yet commercially available; however, they can be applied on a large scale.12

Three years ago, a commercial HPV detection test, hybrid capture (HC), was introduced.13–15 Hybrid capture is a non-radioactive, relatively rapid, liquid hybridisation assay designed to detect 14 HPV types, divided into high risk (types 16, 18, 31, 33, 35, 45, 51, 52, and 56) and low risk (types 6, 11, 42, 43, and 44) groups. This test has been proposed for routine use on large series of women to improve the sensitivity and negative predictive value of screening for SIL.16 It can be applied to biopsy specimens7 and cervical lavage,14 but its principal application is with cervical scrapes. The first studies were particularly promising, showing a good agreement with PCR results, although the method was less sensitive, with detection rates for high risk HPV DNA of 83%, and 93% for high grade SIL.17–19 These papers and the following studies of selected populations concluded that screening for cervical intraepithelial neoplasias (CIN) grades 2/3 could be significantly improved by HPV testing with the hybrid capture assay. Nevertheless, in our own experience on a series of 1028 women attending routine screening, the overall sensitivity in detecting high grade SIL with hybrid capture was 71.2% and its positive predictive value was 17.8%.20 Classical cytological screening remained the most sensitive tool (84%) to detect high grade SIL, with a positive predictive value of 91.3%. Thus we concluded that the crude sensitivity of the hybrid capture limited its use for the screening of high grade lesions on a large scale.

Since this study, a second generation of hybrid capture has been commercialised—hybrid capture II (Digene) (HC II), using microtitre plates instead of tubes and detecting four additional viral oncogenic types (types 39, 58, 59 and 68). The preliminary studies give
more reliable results, with a lower detection limit of 0.2 to 1 pg HPV DNA/ml. The aim of the present study was to compare the performance of high risk HPV in cervical lesions—which is well known, especially with PCR analysis—but also to evaluate the sensitivity and specificity of HC II test as compared with the results obtained with the previous hybrid capture assay (HC I) and data provided by PCR for HPV detection in routine clinical use.

**Methods**

We studied 42 fresh cone excision biopsy samples following the discovery of high grade SIL on a previous biopsy. Cervical cells were collected with cytobrushes (Medscan) on fresh samples just before surgery. Specimens for HPV DNA testing were suspended in 1 ml of ViraPap/Viratype transport medium (Digene) and stored at −20°C until further processing. The same cervical scrape was used for the HC I and HC II tests and 200 µl of the sample were stored for PCR.

HPV DNA detection was performed by the two commercially available hybrid capture techniques (Digene): HC I and HC II. All scrapes were analysed for the presence of low risk HPV types 6, 11, 42, 43, and 44 and high risk HPV types 16, 18, 31, 33, 35, 45, 51, 52, and 56. Types 39, 58, 59, and 68 only were detected with the HC II assay. This enzyme linked immunosorbent assay is based on a sandwich hybridisation followed by a non-radioactive alkaline phosphatase reaction with chemiluminescence in tubes (HC I) and in microplates (HC II).

Samples were classified as positive for HPV DNA if the relative light unit reading obtained from the luminometer was equal to or greater than the mean of the positive control values. As some investigators have reported that increased HPV DNA level of high risk HPV types was the principal predictor of CIN, we used as proposed the ratio of relative light units to positive control values to quantify high risk HPV DNA in our samples.

In parallel, we performed PCR according to the protocol of de Roda Husman et al using GP5+/GP6+ primers, after DNA extraction from the cervical scrapes to detect HPV DNA. This method allows the detection of 23 HPV types (types 6, 11, 13, 16, 18, 30, 31, 32, 33, 34, 35, 39, 40, 43, 45, 51, 52, 54, 55, 56, 58, 59, and 66). The typing of HPV I is performed by dot-blot on amplimers with digoxigenin labelled HPV plasmid probes for HPV types 6, 11, 16, 18, 31, 33, and 35.
New sensitive test for human papillomavirus detection

Table 3  Evaluation of the viral load by HC II according to the maximum size of cervical intraepithelial neoplasia

<table>
<thead>
<tr>
<th>Viral load (ratio)</th>
<th>1–3 mm</th>
<th>3–5 mm</th>
<th>5–10 mm</th>
<th>&gt;10 mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>&lt;50</td>
<td>4</td>
<td>3</td>
<td>2</td>
<td>3</td>
</tr>
<tr>
<td>50–100</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>100–200</td>
<td>0</td>
<td>0</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>200–500</td>
<td>1</td>
<td>3</td>
<td>1</td>
<td>0</td>
</tr>
<tr>
<td>&gt;500</td>
<td>2</td>
<td>1</td>
<td>0</td>
<td>1</td>
</tr>
</tbody>
</table>

HC, hybrid capture.

Table 2 shows the evaluation of the viral load for the detection of high grade lesions obtained by HC II. Table 3 shows the evaluation of the viral load according to the maximum size of the CIN in our specimens.

Discussion

In this study we compare the data obtained with three techniques detecting HPV DNA used for the detection of high grade lesions. We emphasise that the entire cone excision biopsy sample was histologically examined and so the final diagnosis of the lesions was definitive. This approach allowed us to obtain a good correlation between HPV detection and the cervical lesions. We did not detect any low risk HPV. This is not surprising since all of our cone excision biopsies were justified by previous histological diagnoses of high grade lesions generally related to high risk HPV. In 14 samples (nine inflammatory and five low grade lesions), high grade lesions were not detected. The previous biopsy may have excised the initial lesion. PCR remains the most sensitive method for detecting HPV DNA (27 of 28 high grade lesions (96.4%), with a specificity of 66.7%). HC II had a sensitivity of 92.8% and a specificity of 66.7%, while HC I had a sensitivity of 71.4% and a specificity of 88.9%. These latter results confirm our previous data on the sensitivity of HC I tested on cone biopsy samples and the findings of Nind et al using the same comparative methodology on high grade cervical lesions. Our results with HC II were almost equivalent to those obtained with PCR. This rapid (five hours of handling), reliable, and sensitive assay seems very promising for detecting HPV DNA in routine clinical practice.

Cuzick et al showed that in women with cytological abnormalities, HPV positivity at a high level, detected by a semiquantitative PCR, was strongly related to high grade CIN. Ho et al have also suggested that cases of SIL with a high viral load are more likely to persist than those with a low level of HPV DNA. Thus a high viral load of oncogenic HPV DNA may be considered a risk factor for potentially evolving low grade lesions as well as in high grade lesions. This variable can be semiquantitatively evaluated by the relative light unit values provided by the hybrid capture assay. Indeed, in none of the nine cases showing a low viral load (< 30) with the more sensitive HC II was high risk HPV DNA detected with HC I. Nevertheless, high grade lesions were not systematically associated with a high viral load. In our experience, for a ratio of cervical sample to normal control of > 200, the sensitivity for the detection of high grade lesions was only 34.6%, with a specificity of 83.3%. We had similar findings with the previous HC I assay.

The variability of the viral loads in high grade lesions may be explained by the low amount of oncogenic HPV DNA detectable when the viral DNA is integrated in the host genome, while in other circumstances viral DNA may also be present and abundant in its episomal form. The size of the lesions may also determine the numbers of exfoliated infected cells in cervical scrapes. However, we did not find any significant correlation between extension of the CIN and the viral load detected by the HC II assay in our cone excision biopsy samples (table 3). Thus the quantitative approach provided by the HC II cannot clearly discriminate between cases with and without high grade lesions.

In conclusion, HPV detection with the HC-II assay is more sensitive than the previous HC I. It represents a rapid and promising test for routine use. Nevertheless the viral load detected by this test was not a reliable predictor of high grade lesions. Thus the utility and efficacy of HPV detection with HC II needs to be compared with non-radioactive GP5+/6+ PCR for detecting high grade lesions in routine screening on larger populations.

This work was supported by the CHU (Centre Hospitalier et Universitaire) of Reims, the ARC (Association pour la Recherche contre le Cancer), and the Lion’s Clubs of Soissons and Villers Cotterets.


Hybrid capture II, a new sensitive test for human papillomavirus detection. Comparison with hybrid capture I and PCR results in cervical lesions.

C Clavel, M Masure, I Putaud, K Thomas, J P Bory, R Gabriel, C Quereux and P Birembaut

J Clin Pathol 1998 51: 737-740
doi: 10.1136/jcp.51.10.737

Updated information and services can be found at:
http://jcp.bmj.com/content/51/10/737

Email alerting service

These include:
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/